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Purpose:  To evaluate the outcome of the part-time occlusion therapy with near activities in monocular 
amblyopic patients according to gender, age, severity of amblyopia, and the cause of amblyopia.
Methods: Fifty eight patients who were prescribed part-time occlusion therapy with near activity from July 
1998 to October 2004, were included in this retrospective study. All patients were divided into groups by 
gender, age, severity of amblyopia, and the cause of amblyopia. Main outcome measures were best 
corrected visual acuity, line improvement, and success rate.
Results: At the end of patch therapy, visual acuity improved from baseline by an average of 3.2±2.5 lines 
(0.33±0.26 log MAR), and follow-up period was 19.71±14.61 months (1.62±1.20 years). At the last follow 
-up, visual acuity improved from baseline by an average of 3.7±2.4 lines (0.38±0.26 log MAR), and 
follow-up period was 37.41±25.83 months (3.08±2.12 years). The success rate was 86% (50 patients) at 
the end of patch therapy. In 44 patients out of 50 patients (88%), the visual acuity was maintained. While 
43 patients out of 47 patients who were less than 7 years old (91%) achieved success, 7 patients out of 
11 patients 7 years or older (64%) achieved success (p=0.035).
Conclusions: Six-hour part-time occlusion treatment combined with near activities appears to be favorable 
in treating 58 children during follow-up of mean 3.08 years. The significant factor was the age at initial treatment.
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Although amblyopia is one of the most common ocular 
disorders in children, preferred treatment modalities and 
dosage vary a great deal among opthmlologists.
1 Occlusion 
therapy and pharmacologic penalization, using atropine and 
other cycloplegic drops, represent two of the most common 
forms of treatment.
1,2 Other forms of treatment, including 
levodopa and carbidopa combination,
3 combined optical and 
atropine penalization,
4 contact lenses, or refractive surgery,
5,6 
have been reported to help with treatment.
Even though occlusion therapy has been the mainstay of 
treatment of amblyopia, opinions vary on the number of 
hours of patching per day.
2,7-11 Some have questioned the 
effectiveness of part-time occlusion therapy, but full-time 
occlusion therapy may have a risk of the occlusion amblyopia 
and poor compliance.
2,12 Especially, young and older children 
may have poor compliance contributed to big social pressure 
from their friends and colleagues. Therefore, we prescribed 
patching only 6 hours per day and recommended combination 
with at least one hour of near-visual activities while patching 
to prevent the side effect and poor compliance of full-time 
patching.
The aim of this study was to evaluate the outcome of the 
part-time occlusion therapy with near activities in monocular 
amblyopic patients. We studied the success rate, maintenance 
rate of total patients, difference according to the gender, age, 
severity of amblyopia, and the cause of amblyopia, and 
consecutive changes of visual acuity in 12 months.
Materials and Methods 
This retrospective study included 58 Korean monocular 
amblyopic patients with strabismic and/or anisometropic KS  Park,  et  al.  OUTCOMES  OF  6  HOUR  PART-TIME  OCCLUSION  TREATMENT
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　 6-Hour  Group
　 n=58
Gender  [n  (%)]
    Male 28  (48)
    Female 30  (52)
    total   58  (100)
Cause  of  amblyopia  [n  (%)]
    Anisometropia 33  (57)
    Strabismus 14  (24)
    Mixed 11  (19)
    total   58  (100)
Age  (years) 
  M e a n  ( S D
*) 4.86  (1.62)
Refractive  error,  amblyopic  eye
    (spherical  equivalent  in  diopters)
  M e a n  ( S D
*) 3.42  (2.40)
Best  corrected  visual  acuity,  amblyopic  eye 
  D e c i m a l  n o t a t i o n  M e a n  ( S D
*)
  l o g  M A R
†Mean  (SD
*)
0.36  (0.20)
0.54  (0.31)
Best  corrected  visual  acuity,  sound  eye
  D e c i m a l  n o t a t i o n  M e a n  ( S D
*)
  l o g  M A R
†Mean  (SD
*)
0.80  (0.19)
0.13  (0.13)
Interocular  acuity  difference,
  D e c i m a l  n o t a t i o n  M e a n  ( S D
*)
  l o g  M A R
†Mean  (SD
*)
0.44  (0.20)
0.41  (0.27)
* SD=Standard deviation; 
†Log MAR=logarithm of the minimum 
angle  of  resolution.
Table  1.  Demographic  and  baseline  clinical  characteristics
amblyopia from July 1998 to October 2004. Patients were 
recruited from the pediatric ophthalmologic clinic of our 
hospital, according to the tenets of Declaration of Helsinki. 
They were prescribed part-time occlusion therapy combined 
with near activities and showed good compliance.
Eligibility testing included visual acuity, cycloplegic 
refraction, manifested refraction, fundus examination, and 
ocular motility test. The major eligibility criteria for the trial 
included the age from 3 to 10 years, best‐corrected visual 
acuity (BCVA) 20/30 or better in the sound eye, intereye 
visual acuity difference of 2 or more Snellen lines, the 
presence of or a history of an amblyogenic factor for 
strabismus and/or anisometropia, and the wearing of optimal 
spectacle correction for minimum of 4 weeks at the time of 
enrollment. Patients with less than 6 months of follow-up 
after cessation of occlusion therapy were excluded. 
Strabismic amblyopia was defined as amblyopia (1) in the 
presence of either a heterotropia at distance and/or near 
fixation or a history of strabismus surgery and (2) in the 
absence of refractive error meeting the criteria below for 
mixed amblyopia. Anisometropic amblyopia was defined as 
amblyopia in the presence of anisometropia of ≥ 2.00 of 
spherical or ≥ 1.50 of cylinder diopters, with no measurable 
heterotropia at distance or near fixation, which persisted after 
at least 4 weeks of spectacle correction. Mixed amblyopia 
was defined as amblyopia in the presence of (1) either a 
heterotropia at distance and/or near fixation or a history of 
strabismus surgery and (2) anisometropia of ≥  2.00 of 
spherical or ≥ 1.50 of cylinder diopters, with no measurable 
heterotropia at distance or near fixation, which persisted after 
at least 4 weeks of spectacle correction. The exclusion 
criteria were following: (1) presence of an organic, ocular 
cause of reduced visual acuity; (2) prior intraocular surgery; 
(3) known skin reaction to patch or bandage adhesive; and 
(4) prior amblyopia treatment.
All patients followed 6 hours daily occlusion therapy 
(part-time occlusion) with 3 M opticlude, and were followed 
up every 1-4 months. We recommended at least one hour of 
near‐visual activities such as reading a book, dictation, 
computer or video game, and television watching while 
patching. At the first visit, measurement of visual acuity, 
cycloplegic refraction, ocular motility examination, and slit 
lamp examination were performed. After one week, manifested 
refraction was performed. At every visit, measurement of 
visual acuity, manifested refraction, and ocular motility 
examination were performed. Occlusion therapy was 
continued until the vision of the amblyopic eye had no 
further improvement in spite of good compliance after at least 
6 months of constant patching. Treatment success was 
defined as visual acuity more than 20/30, three lines of 
improvement from baseline, or both.
The patients were divided by gender, age (less than 7 
years, 7 years or older), severity of amblyopia; severe (20/400- 
20/100); moderate (20/80-20/40); mild (20/32-), and the 
causes of amblyopia (anisometropia, strabismus, mixed type). 
We evaluated the success rate and the line improvement in 
the amblyopic eye after the occlusion therapy.
We studied consecutive changes of visual acuity in 36 
patients. They were followed up for 12 consecutive months 
and had available data for analysis. They were divided 3 
groups by the cause of amblyopia.
The data were analyzed using SPSS, version 12.0 (SPSS 
Inc, Chicago, IL, USA). Nominal variables, including gender, 
age, the cause of amblyopia, severity of amblyopia, and 
success were analyzed using the Chi square test and Fisher’s 
exact test. Other statistical comparisons among groups used 
t-test and ANOVA. The null hypothesis was rejected at the 
0.05 level of significance.
Results
Total 80 amblyopic patients were enrolled this study and 
58 patients met the study criteria. They included 28 male 
(48%), and 30 female (52%). The identified amblyogenic 
factor was anisometropia in 33 (57%), strabismus in 14 
(24%), and mixed type in 11 (19%). The mean age was 4.86
±1.62 years. The mean refractive error in the amblyopic eye 
at enrollment was spherical equivalent of 3.42±2.40 D. The 
mean best corrected Snellen visual acuity was 0.36±0.20 in 
the amblyopic eye, 0.80±0.19 in sound eye. The interocular 
visual acuity difference was 0.44±0.20 (Table 1).Kor  J  Ophthalmol  Vol.22,  No.1,  2008
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　 Start  patch Stop  patch Last  follow-up
　 (n=58) (n=58) (n=58)
Best  corrected  visual  acuity  score,
    20/400 3  (5) 0 0
    20/200   8  (14) 3  (5) 2  (3)
    20/125 2  (3) 0 0
    20/100 5  (9) 1  (2) 1  (2)
    20/63   7  (12) 2  (3) 2  (3)
    20/50 16  (27)   8  (14) 3  (5)
    20/40   9  (16) 0 3  (5)
    20/32   8  (14) 12  (21) 11  (18)
    20/25 0 15  (26) 13  (23)
    20/20 0 17  (29) 23  (41)
log  MAR
* ( S D
†) 0.54  (0.31) 0.2  (0.25) 0.16  (0.22)
* L o g  M A R = l o g a r i t h m  o f  t h e  m i n i m u m  a n g l e  o f  r e s o l u t i o n ;  
†SD=Standard  deviation.
Table 2. Amblyopic eye visual acuity at the time of start, 
stop  patch,  and  last  follow-up
　 Total  (%) Success  (%) Failure  (%) p-value
Gender  [n  (%)]
    Male 28  (48) 24  (86)   4  (14) 0.916
    Female 30  (52) 26  (87)   4  (13)
Age
    Less  than  7  years 47  (81) 43  (91) 4  (9) 0.035
*
    7  years  or  older 11  (19) 7  (64)   4  (36)
Severity  of  amblyopia  (%)
    Severe  (20/400-20/100) 18  (31) 14  (78)   4  (22) 0.32
    Moderate  (20/80-20/40) 32  (55) 28  (88)   4  (12)
    Mild  (20/32-)   8  (14)     8  (100) 0  (0)
Cause  of  amblyopia  [n  (%)]
    Anisometropia 33  (57) 29  (88)   4  (12) 0.39
    Strabismus 14  (24) 13  (93) 1  (7)
    Mixed 11  (19)   8  (73)   3  (27)
* p<0.05.
Table  4.  Success  rate  according  to  each  factor  at  the  end  of  patch  therapy
Authors
(ref.  no.)
Average  Follow-up
(years)
%  Visual  Acuity 
Maintained  or 
Improved
Malik  et  al.
17 1-5.5 46
Sparrow  &  Flynn.
18 5.4 40
Bowman  et  al.
19 47 9
Levartovsky  et  al.
20 6.4 45
Leiba  et  al.
21 21.5 66.7
Current  study 1.45 88
Table  3.  Maintenance  of  visual  acuity  after  occlusion 
treatment  for  amblyopia
Among the 33 anisometropic amblyopic patients, 14 had 
hypermetropia (mean spherical equivalent 4.38±2.05 D, 6 
had myopia (mean spherical equivalent 5.94±1.24 D), and 
13 had astigmatism (mean spherical equivalent 1.39±1.62 
D). Among the 14 strabismic amblyopic patients, 3 had 
refractive accommodative esotropia (mean 13.33±5.80 
prism deviation), 4 had partially accommodative esotropia 
(mean 48.75±8.50 prism deviation), 2 had nonrefractive 
accommodative esotropia (mean 32.50±3.50 prism deviation), 
3 had intermittent exotropia, basic pattern (mean 25.00±5.00 
prism deviation), 1 had comitant left hypertropia (30 prism 
deviation) and 1 right dissociated vertical deviation (10 prism 
deviation). Among the 11 mixed type amblyopic patients, 3 
had refractive accommodative esotropia (mean 23.33±2.89 
prism deviation), 3 had nonrefractive accommodative esotropia 
(mean 35.00±5.00 prism deviation), and 5 had intermittent 
exotropia, basic pattern (mean 29.00±12.45 prism deviation).
Substantial improvement in visual acuity was achieved 
(Table 2). At the end of patch therapy, visual acuity 
improved from baseline by an average of 3.2±2.5 lines (0.33
±0.26 log MAR), and follow-up period was 19.71±14.61 
months (1.62±1.20 years). At the last follow-up, visual 
acuity improved from baseline by an average of 3.7±2.4 
lines (0.38±0.26 log MAR) and follow-up period was 37.41
±25.83 months (3.08±2.12 years).
Fifty patients showed successful results at the end of patch 
therapy (data now shown). In 44 patients out of 50 patients, 
the visual acuity was maintained until the last follow-up 
(Table 3). In 47 patients less than 7 years, 43 (91%) achieved 
successful results. In 11 patients 7 years or over, 7 (64%) 
achieved successful results. In terms of age, there was a 
statistically significant difference of success rate between the 
two groups, (p=0.035) but not in terms of gender, severity 
of amblyopia, cause of amblyopia (Table 4).
At the end of patch therapy, visual acuity improved by 
5.22±3.24 lines in 18 patients with severe amblyopia 
(20/400-20/100), by 2.59±1.46 lines in 32 moderate 
amblyopia (20/80-20/40), and by 1.38±0.74 lines in 8 mild 
amblyopia (20/32-). In terms of severity of amblyopia, there 
was significant difference of visual acuity improvement KS  Park,  et  al.  OUTCOMES  OF  6  HOUR  PART-TIME  OCCLUSION  TREATMENT
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　 Total  (%) Line  improvement  (SD) p-value
Gender  [n  (%)]
    Male 28  (48) 3.29  (2.52) 0.898
    Female 30  (52) 3.20  (2.54)
Age
    Less  than  7  years 47  (81) 3.40  (2.50) 0.328
    7  years  or  older 11  (19) 2.55  (2.54)
Severity  of  amblyopia  (%)
    Severe  (20/400-20/100) 18  (31) 5.22  (3.23) <0.001
*
    Moderate  (20/80-20/40) 32  (55) 2.59  (1.46)
    Mild  (20/32-)   8  (14) 1.38  (0.74)
Cause  of  amblyopia  [n  (%)]
    Anisometropia 33  (57) 3.30  (2.57) 0.65
    Strabismus 14  (24) 3.57  (2.65)
    Mixed 11  (19) 2.64  (2.25)
* p<0.05.
Table  5.  Line  improvement  according  to  each  factor  at  the  end  of  patch  therapy
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Fig. 1. Change of visual acuity according to cause of amblyopia in 
12  months.
among the three groups (p<0.001) (Table 5).
Consecutive changes of visual acuity were evaluated in 36 
patients who could be followed up for 12 months (Fig. 1). 
Gradual linear improvement of visual acuity was noted. 
There were two steep slopes in the curve, at 3-4 months and 
at 11-12 months.
Discussion
There have been many arguments about the amount of 
occlusion treatment. Some have suggested full-time occlusion 
treatment and others have suggested part-time occlusion 
treatment, a few hours per day. In a PEDIG trial, 6 hours 
per day occlusion treatment produced an improvement in 
visual acuity that was of similar magnitude to the 
improvement by full-time occlusion treatment in severely 
amblyopic children 3 to less than 7 years of age.
11 Other 
reports also suggests part-time occlusion treatment; one hour 
or more is effective in many children.
10-14 In considering side 
effects due to long time occlusion treatment, such as social 
stress, irritation and allergy, part-time occlusion treatment 
should be preferred.
We evaluated the outcome of 6 hour of daily occlusion 
treatment with near visual activity in monocular amblyopia. 
The primary outcome was best corrected visual acuity 
measured each month during follow up. The distribution of 
visual acuity and line improvement has been shown in table 
2. Study group had improved by an average of 3.2 lines at 
the end of patch therapy. The PEDIG study has shown the 
improvement of 2.4 lines in 2 hour-patching group and 6 
hour-patching group.
10 The study by Awan et al have shown 
the improvement of 2.4 lines in no patching group, 2.9 lines 
in 3 hour-patching group, and 3.4 lines in 6 hour-patching 
group.
13 The result of our study is not different from other 
studies (Table 5).
In other reports,
15-19 the percentage of treated eyes that 
maintained their visual acuity after termination of occlusion 
treatment varied widely, ranging from 40% to 79%. In our 
study, during the 1.45 years between cessation of treatment 
and the present examination, visual acuity was maintained or 
had improved in 88% of the treated eyes (Table 3). Although 
a number of parameters of our study, such as age at onset 
of therapy, duration of therapy, and age at final assessment, 
was different from previous studies, our results show a 
similar or higher rate of visual acuity maintenance.
In this study, the most significant factor for visual outcome 
was age (P=0.035) (Table 4). Previous reports showed 
reduced improvement in the older children and higher success 
rate in the younger children.
11,20 Previous studies
22-24 reported 
that amblyopia can be treated beyond 7 years of age; the Kor  J  Ophthalmol  Vol.22,  No.1,  2008
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success rate in children 7 years or older in this study was 
64%. In a PEDIG trial
24 for 7 to 17-year-olds with amblyopia 
ranging from 6/12 to 6/120, 53% of 7 to 12-year-old children 
responded, to amblyopia treatment with at least ten letters on 
the ETDRS chart, whereas 25% responded to optical 
correction alone. In 13 to 17-year-old children who had not 
been previously treated, 47% responded to amblyopia 
treatment and 20% responded to optical correction alone.
In other factors, there was no statistical significance. 
However, as in previous reports,
20-29 our study showed that 
success rate in children with mild amblyopia was higher than 
that in other children (P=0.32) (Table 4). Although the 
success rate in severe amblyopia was lower than others, it 
was still over 50%. In terms of causes of amblyopia, success 
rate in children with mixed type amblyopia was lower than 
that in children with other causes (P=0.39) (Table 4).
In our study, severity of amblyopia was not a significant 
factor toward visual outcome, perhaps due to poor cooperation 
and selection bias. Children with severe amblyopia are 
detected at an earlier age than other children and the young 
children may not cooperate readily to tests. As they become 
older, they may be checked for more accurate visual acuity 
and thus exaggerate the good success rate of children with 
severe amblyopia.
In more severe amblyopia, there was more line improvement, 
and it was statistically significant (p<0.001) (Table 5). 
Therefore, we must not give up the treatment in severe 
amblyopia. Other factors did not show significant differences.
The 36 patients who could be followed up for 12 months 
showed two steep slopes in the curve, at 3-4 months and at 
11-12 months (Fig. 1). It may mean that the effect of 
occlusion treatment is maximum during the first 3-4 months. 
It confirms a previous report that there is maximal influence 
within the first 3 months of initiation of occlusion and it may 
extend to 6 months.
21
One factor for good outcome in our study was near 
activities while patching. Although many doctors recommend 
children to do near activities that need hand-eye 
coordination while patching and they believe it is successful 
in improving visual acuity in most children, it was unclear 
whether near activities enhance the effect of occlusion 
treatment or not. A pilot study
25 by PEDIG suggested that 
children receiving occlusion treatment combined with near 
activities, actually spent more time performing those activities.
Our study has some limitations. It includes only patients 
who received the treatment of 6 hour part-time occlusion. We 
do not report a comparison group with full-time occlusion 
treatment because we seldom recommend full-time occlusion. 
Another weakness is that this is a retrospective study based 
on medical records. Patients in each group are few in number 
and there may be a selection bias. And the duration of our 
study is shorter than that of other studies which show the 
maintenance of improved vision. With longer follow-up, 
success maintenance may be decreased.
In conclusion, our 6 hour part-time occlusion treatment 
combined with near activities appears to be favorable in 
treating 58 children during follow-up time of mean 3.08 
years. Total success rate was 86% (50 patients) and 44 
(88%) of them maintained or increased their visual acuity 
in average 1.45 years after end of occlusion treatment. The 
statistically significant factor influencing success rate was 
the age of the subject at the start of treatment. 
Improvement of visual acuity was maximal within 3-4 
months of occlusion treatment.
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